As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing?
•Chinese biotech companies have become profitable due to record-breaking cross-border deals in the first half of the year.
•Multinational drugmakers are now indicating a shift towards tighter budget constraints for new partnerships.
•Analysts note that out-licensing deals have surpassed IPOs as the primary funding source for struggling Chinese biotech firms.
→Chinese biotech companies have become profitable due to record-breaking cross-border deals in the first half of the year.
→Multinational drugmakers are now indicating a shift towards tighter budget constraints for new partnerships.
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة South China Morning Post. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by South China Morning Post. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
